IMVT

Immunovant, Inc.

September 23, 2026 · pre-market

Rarity

2.08

Peak move

−9.68%

Float cap

$3.0B

Immunovant is a clinical-stage immunology company developing IMVT-1402 (imeroprubart), an anti-FcRn antibody for autoimmune diseases driven by pathogenic IgG antibodies. It is evaluating the candidate in patients with conditions such as Graves' disease, myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, rheumatoid arthritis, Sjögren's disease, and cutaneous lupus erythematosus.

• clinical_readoutSep 23

  Immunovant reported topline Period 1 results from its 57-patient proof-of-concept trial (NCT06980805) of IMVT-1402 (imeroprubart) in cutaneous lupus erythematosus, which missed statistical significance on the primary endpoint of percent change from baseline in CLASI-A score at Week 12, and the company will stop development in CLE.

  Webtmcnet.comWebthepharmaletter.comWebcentralcharts.comWebbenzinga.comWebmarketscreener.comWebbenzinga.com
• analyst_ratingSep 23

  Guggenheim Securities analysts characterized Immunovant's CLE trial as a fact-finding proof-of-concept study in a competitive landscape and said they were a bit cautious on the readout ahead of the data.

  Webfiercebiotech.com
• analyst_ratingSep 21

  Piper Sandler maintained a Buy rating on Immunovant (IMVT) with a $66 price target on September 21, 2026.

  Webstockanalysis.com